3-iodobenzylguanidine has been researched along with Adrenocortical Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Charalampopoulos, A; Farrugia, FA; Martikos, G; Misiakos, E; Surgeon, C; Tzanetis, P; Zavras, N | 1 |
| Brauckhoff, M; Dralle, H | 1 |
2 review(s) available for 3-iodobenzylguanidine and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Radiology of the adrenal incidentalomas. Review of the literature.
Topics: 3-Iodobenzylguanidine; Addison Disease; Adrenal Cortex Neoplasms; Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenocortical Adenoma; Adrenocortical Carcinoma; Cushing Syndrome; Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Hemorrhage; Humans; Hyperaldosteronism; Indium; Indium Radioisotopes; Lymphoma; Magnetic Resonance Imaging; Myelolipoma; Octreotide; Pheochromocytoma; Positron-Emission Tomography; Radionuclide Imaging; Radiopharmaceuticals; Tomography, X-Ray Computed; Ultrasonography | 2017 |
[Recurrent operations on the adrenal glands].
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymph Node Excision; Male; Middle Aged; Mitotane; Neoplasm Recurrence, Local; Octreotide; Palliative Care; Paraneoplastic Endocrine Syndromes; Pheochromocytoma; Radiotherapy, Adjuvant; Reoperation | 2005 |